Skip to main content Back to Top
Advertisement

2/14/2020

Anagrelide Hydrochloride Capsules

Products Affected - Description

    • Agrylin oral capsule, Shire (Takeda), 0.5 mg, bottle, 100 count, NDC 54092-0063-01
    • Anagrelide Hydrochloride oral capsule, Teva, 0.5 mg, bottle, 100 count, NDC 00172-5241-60
    • Anagrelide Hydrochloride oral capsule, Teva, 1 mg, bottle, 100 count, NDC 00172-5240-60
    • Anagrelide Hydrochloride oral capsule, Torrent, 0.5 mg, bottle, 100 count, NDC 13668-0453-01
    • Anagrelide Hydrochloride oral capsule, Torrent, 1 mg, bottle, 100 count, NDC 13668-0462-01 - discontinued

Reason for the Shortage

    • Shire (Takeda) did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.
    • Torrent has discontinued anagrelide 1 mg capsules. Torrent is working on relaunching anagrelide 0.5 mg capsules.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Takeda has Agrylin 0.5 mg capsules on allocation.
    • Teva has anagrelide 0.5 mg and 1 mg capsules on back order and the company estimates a release date of late-March 2020.
    • Torrent has anagrelide 0.5 mg and 1 mg capsules on allocation.

Updated

Updated February 14, 2020 by Anthony Trovato, PharmD, BCPS. Created November 15, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins